Menu
← Oncology Approval Tracker
FDA DECISION ·
Rozlytrek oral pellets
entrectinib · Genentech
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
The oral pellet formulation was approved for the same age-expanded NTRK fusion-positive solid tumor indication in adults and children older than one month. The label covers metastatic disease or cases where surgery would likely cause severe morbidity, with progression after treatment or no satisfactory alternative, and excludes known acquired resistance mutations.
LAMPGEN ANALYSIS
Why it matters
The new presentation provides a separate administration option for a population that includes young children.
What research teams should watch
Check the formulation-specific label, weight and how caregivers will prepare and administer the dose.
PRIMARY RECORDS